NHP iPSC-Derived Cardiomyocytes for Translational Cardiac Profiling

This poster presents Ncardia’s non-human primate (NHP) iPSC-derived ventricular cardiomyocyte platform, designed to bridge the gap between in vitro and in vivo studies for gene and cell therapy development. 

Download it now for a closer look at:

• How NHP iPSC-derived cardiomyocytes can be produced at scale with high purity and stable functional properties, supporting consistent experimental outcomes 
  
• Comparative data highlighting key electrophysiological and contractile differences between human and NHP cardiomyocytes under baseline and drug-treated conditions 
• Insights into species-specific responses to pharmacological compounds, supporting better interpretation of translational safety data
• How this platform enables repeated, long-term functional assessment in a controlled in vitro environment, complementing in vivo NHP studies

• How integrated MEA and impedance assays enable detailed functional profiling, including beat rate, arrhythmia, and contractility responses over time